OBJECTIVE: The objective of this study was to assess suitability of dual-time-point 18F-FDG [(18F)-fluoro-2-deoxyglucose]-PET imaging for differentiating between malignant and benign pulmonary lesions, whose size and maximal standardized uptake values (SUVs) are greater than 10 mm and 2.5, respectively. METHODS: A total of 38 patients, 27 with malignant lesions (n = 30), and 11 with benign lesions (n = 22), were investigated by performing two static acquisitions started at mean times t = 79 and t = 158 min after the tracer injection. A model analysis involving tissue 18F-FDG uptake and release has been developed and applied. RESULTS: Malignant lesions showed a SUV increase between the two acquisitions for 27 of 30 lesions, and a SUV decrease or constancy for the other three. Benign lesions showed a SUV increase in 19 of 22 lesions, and a SUV decrease in three (both increase and decrease were observed for multiple benign lesions in two patients). CONCLUSION: It is recommended that dual-time-point 18F-FDG-PET imaging is not indicated to differentiate between malignant and benign pulmonary lesions, whose size and maximal SUV are greater than 10 mm and 2.5, respectively. Furthermore, a model analysis suggests that the variation in SUV observed between early and delayed scans may be explained by different values of the 18F-FDG release/uptake ratio.
OBJECTIVE: The objective of this study was to assess suitability of dual-time-point 18F-FDG [(18F)-fluoro-2-deoxyglucose]-PET imaging for differentiating between malignant and benign pulmonary lesions, whose size and maximal standardized uptake values (SUVs) are greater than 10 mm and 2.5, respectively. METHODS: A total of 38 patients, 27 with malignant lesions (n = 30), and 11 with benign lesions (n = 22), were investigated by performing two static acquisitions started at mean times t = 79 and t = 158 min after the tracer injection. A model analysis involving tissue 18F-FDG uptake and release has been developed and applied. RESULTS: Malignant lesions showed a SUV increase between the two acquisitions for 27 of 30 lesions, and a SUV decrease or constancy for the other three. Benign lesions showed a SUV increase in 19 of 22 lesions, and a SUV decrease in three (both increase and decrease were observed for multiple benign lesions in two patients). CONCLUSION: It is recommended that dual-time-point 18F-FDG-PET imaging is not indicated to differentiate between malignant and benign pulmonary lesions, whose size and maximal SUV are greater than 10 mm and 2.5, respectively. Furthermore, a model analysis suggests that the variation in SUV observed between early and delayed scans may be explained by different values of the 18F-FDG release/uptake ratio.
Authors: Gang Cheng; Abass Alavi; Esther Lim; Thomas J Werner; Catherine V Del Bello; Scott R Akers Journal: Mol Imaging Biol Date: 2013-06 Impact factor: 3.488
Authors: O A Catalano; E Nicolai; B R Rosen; A Luongo; M Catalano; C Iannace; A Guimaraes; M G Vangel; U Mahmood; A Soricelli; M Salvatore Journal: Br J Cancer Date: 2015-04-14 Impact factor: 7.640